Potential pitfalls of reproductive direct-to-consumer testing
Frank Z. Stanczyk, Ph.D.,
Rachel S. Mandelbaum, M.D.,
Rogerio A. Lobo, M.D.
Affiliations
Frank Z. Stanczyk, Ph.D.
Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, California; Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California; Reprint requests: Frank Z. Stanczyk, Ph.D., Reproductive Endocrine Research Laboratory, 333 S. Arroyo Parkway, Rm 2, Pasadena, CA 91105
Rachel S. Mandelbaum, M.D.
Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, California
Rogerio A. Lobo, M.D.
Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, New York
The availability of direct-to-consumer (DTC) testing has dramatically increased over the past 2 decades, particularly those targeted at reproduction and fertility. Several ethical concerns exist with regard to DTC tests, including the lack of governmental regulation and consumer protection, standardized laboratory methodology, and clinical validity and actionability. Physicians must familiarize themselves with the pitfalls of DTC tests to best aid patients in interpreting DTC test results and guide them toward evidence-based treatment plans.
